Around 300 million individuals are affected by major depressive disorder (MDD) in the world. Despite this high number of affected individuals, more than 50% of patients do not respond to antidepressants approved to treat MDD. Patients with MDD that do not respond to 2 or more first-line antidepressant treatments are considered to have treatment-resistant depression (TRD). Animal models of depression are important tools to better understand the pathophysiology of MDD as well as to help in the development of novel and fast antidepressants for TRD patients. This review will emphasize some discovery strategies for TRD from studies on animal models, including, antagonists of N-methyl-D-aspartate (NMDA) receptor (ketamine and memantine), electroconvulsive therapy (ECT), lithium, minocycline, quetiapine, and deep brain stimulation. Animal models of depression are not sufficient to represent all the traits of TRD, but they greatly aid in understanding the mechanism by which therapies that work for TRD exert antidepressant effects. Interestingly, these innovative therapies have mechanisms of action different from those of classic antidepressants. These effects are mainly related to the regulation of neurotransmitter activity, including general glutamate and increased connectivity, synaptic capacity, and neuroplasticity.
Keywords: Deep brain stimulation; Electroconvulsive therapy; N-methyl-D-aspartate antagonist; Quetiapine; Treatment-resistant depression.
Copyright © 2019 by S. Karger AG, Basel.
Conflict of interest statement
The authors have no conflicts of interest to declare.
Intravenous Ketamine for Adults with Treatment-Resistant Depression or Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines [Internet].Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Oct 24. Canadian Agency for Drugs and Technologies in Health. 2019. PMID: 31873996 Free Books & Documents. Review.
Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.Neuropharmacology. 2016 Jan;100:17-26. doi: 10.1016/j.neuropharm.2015.07.028. Epub 2015 Jul 26. Neuropharmacology. 2016. PMID: 26211972 Review.
[Treatment resistant depression: actuality and perspectives in 2017].Rev Med Brux. 2017;38(1):16-25. Rev Med Brux. 2017. PMID: 28525197 Review. French.
Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression.Prog Neuropsychopharmacol Biol Psychiatry. 2016 Oct 3;70:117-26. doi: 10.1016/j.pnpbp.2016.03.009. Epub 2016 Apr 1. Prog Neuropsychopharmacol Biol Psychiatry. 2016. PMID: 27046518 Review.
The role of ketamine in treatment-resistant depression: a systematic review.Curr Neuropharmacol. 2014 Sep;12(5):444-61. doi: 10.2174/1570159X12666140619204251. Curr Neuropharmacol. 2014. PMID: 25426012 Free PMC article.
Cited by 1 article
Functional and Dysfunctional Neuroplasticity in Learning to Cope with Stress.Brain Sci. 2020 Feb 24;10(2):127. doi: 10.3390/brainsci10020127. Brain Sci. 2020. PMID: 32102272 Free PMC article.